Impaired insulin secretion in human diabetes mellitus. Effect of pharmacological activation of gamma-aminobutyric acid system

Antonio Quatraro, Giuseppe Consoli, Aldo Stante, Arcangelo Minei, Antonio Ceriello, Nicola Passariello, Dario Giugliano

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

To evaluate whether the gamma-aminobutyric acid (GABA)ergic system plays a role in the defective insulin secretion in human diabetes mellitus, 15 non-insulin-dependent diabetics with fasting hyperglycemia above 140 mg/dl were submitted to two consecutive i.v. glucose tolerance tests (IVGTT) (0.33 g/kg b.w.), in basal conditions and after pharmacologic activation of the GABA system with baclofen and sodium valproate. Baclofen, a synthetic analogue, was given to 8 diabetics in two divided doses of 10 mg each 8 h and 1 h before the post-treatment test; sodium valproate, a drug that increases endogenous GABA activity, was given orally (800 mg) 60 min before the performance of the post-treatment IVGTT. Neither treatment brought about significant changes in insulin, C-peptide, glucagon or growth hormone responses to i.v. glucose nor did they significantly change glucose disappearance rates. These results seem to indicate that GABA does not play a major role in the pathogenesis of defective insulin secretion in non-insulin-dependent diabetes mellitus.

Original languageEnglish
Pages (from-to)23-28
Number of pages6
JournalActa Diabetologica Latina
Volume23
Issue number1
DOIs
Publication statusPublished - Jan 1986

Fingerprint

gamma-Aminobutyric Acid
Diabetes Mellitus
Pharmacology
Insulin
Baclofen
Valproic Acid
Glucose Tolerance Test
Type 2 Diabetes Mellitus
Glucose
Peptide Hormones
C-Peptide
Glucagon
Hyperglycemia
Growth Hormone
Fasting
Pharmaceutical Preparations

Keywords

  • Baclofen
  • Insulin response to glucose
  • Non-insulin-dependent diabetes mellitus
  • Sodium valproate

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Impaired insulin secretion in human diabetes mellitus. Effect of pharmacological activation of gamma-aminobutyric acid system. / Quatraro, Antonio; Consoli, Giuseppe; Stante, Aldo; Minei, Arcangelo; Ceriello, Antonio; Passariello, Nicola; Giugliano, Dario.

In: Acta Diabetologica Latina, Vol. 23, No. 1, 01.1986, p. 23-28.

Research output: Contribution to journalArticle

Quatraro, Antonio ; Consoli, Giuseppe ; Stante, Aldo ; Minei, Arcangelo ; Ceriello, Antonio ; Passariello, Nicola ; Giugliano, Dario. / Impaired insulin secretion in human diabetes mellitus. Effect of pharmacological activation of gamma-aminobutyric acid system. In: Acta Diabetologica Latina. 1986 ; Vol. 23, No. 1. pp. 23-28.
@article{d3fccc90ba1f4f4bb775b81135b6c3f7,
title = "Impaired insulin secretion in human diabetes mellitus. Effect of pharmacological activation of gamma-aminobutyric acid system",
abstract = "To evaluate whether the gamma-aminobutyric acid (GABA)ergic system plays a role in the defective insulin secretion in human diabetes mellitus, 15 non-insulin-dependent diabetics with fasting hyperglycemia above 140 mg/dl were submitted to two consecutive i.v. glucose tolerance tests (IVGTT) (0.33 g/kg b.w.), in basal conditions and after pharmacologic activation of the GABA system with baclofen and sodium valproate. Baclofen, a synthetic analogue, was given to 8 diabetics in two divided doses of 10 mg each 8 h and 1 h before the post-treatment test; sodium valproate, a drug that increases endogenous GABA activity, was given orally (800 mg) 60 min before the performance of the post-treatment IVGTT. Neither treatment brought about significant changes in insulin, C-peptide, glucagon or growth hormone responses to i.v. glucose nor did they significantly change glucose disappearance rates. These results seem to indicate that GABA does not play a major role in the pathogenesis of defective insulin secretion in non-insulin-dependent diabetes mellitus.",
keywords = "Baclofen, Insulin response to glucose, Non-insulin-dependent diabetes mellitus, Sodium valproate",
author = "Antonio Quatraro and Giuseppe Consoli and Aldo Stante and Arcangelo Minei and Antonio Ceriello and Nicola Passariello and Dario Giugliano",
year = "1986",
month = "1",
doi = "10.1007/BF02581350",
language = "English",
volume = "23",
pages = "23--28",
journal = "Acta Diabetologica",
issn = "0940-5429",
publisher = "Springer-Verlag Italia s.r.l.",
number = "1",

}

TY - JOUR

T1 - Impaired insulin secretion in human diabetes mellitus. Effect of pharmacological activation of gamma-aminobutyric acid system

AU - Quatraro, Antonio

AU - Consoli, Giuseppe

AU - Stante, Aldo

AU - Minei, Arcangelo

AU - Ceriello, Antonio

AU - Passariello, Nicola

AU - Giugliano, Dario

PY - 1986/1

Y1 - 1986/1

N2 - To evaluate whether the gamma-aminobutyric acid (GABA)ergic system plays a role in the defective insulin secretion in human diabetes mellitus, 15 non-insulin-dependent diabetics with fasting hyperglycemia above 140 mg/dl were submitted to two consecutive i.v. glucose tolerance tests (IVGTT) (0.33 g/kg b.w.), in basal conditions and after pharmacologic activation of the GABA system with baclofen and sodium valproate. Baclofen, a synthetic analogue, was given to 8 diabetics in two divided doses of 10 mg each 8 h and 1 h before the post-treatment test; sodium valproate, a drug that increases endogenous GABA activity, was given orally (800 mg) 60 min before the performance of the post-treatment IVGTT. Neither treatment brought about significant changes in insulin, C-peptide, glucagon or growth hormone responses to i.v. glucose nor did they significantly change glucose disappearance rates. These results seem to indicate that GABA does not play a major role in the pathogenesis of defective insulin secretion in non-insulin-dependent diabetes mellitus.

AB - To evaluate whether the gamma-aminobutyric acid (GABA)ergic system plays a role in the defective insulin secretion in human diabetes mellitus, 15 non-insulin-dependent diabetics with fasting hyperglycemia above 140 mg/dl were submitted to two consecutive i.v. glucose tolerance tests (IVGTT) (0.33 g/kg b.w.), in basal conditions and after pharmacologic activation of the GABA system with baclofen and sodium valproate. Baclofen, a synthetic analogue, was given to 8 diabetics in two divided doses of 10 mg each 8 h and 1 h before the post-treatment test; sodium valproate, a drug that increases endogenous GABA activity, was given orally (800 mg) 60 min before the performance of the post-treatment IVGTT. Neither treatment brought about significant changes in insulin, C-peptide, glucagon or growth hormone responses to i.v. glucose nor did they significantly change glucose disappearance rates. These results seem to indicate that GABA does not play a major role in the pathogenesis of defective insulin secretion in non-insulin-dependent diabetes mellitus.

KW - Baclofen

KW - Insulin response to glucose

KW - Non-insulin-dependent diabetes mellitus

KW - Sodium valproate

UR - http://www.scopus.com/inward/record.url?scp=0022515697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022515697&partnerID=8YFLogxK

U2 - 10.1007/BF02581350

DO - 10.1007/BF02581350

M3 - Article

C2 - 3012923

AN - SCOPUS:0022515697

VL - 23

SP - 23

EP - 28

JO - Acta Diabetologica

JF - Acta Diabetologica

SN - 0940-5429

IS - 1

ER -